what is nad+.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in all eukaryotic cells. It is the principal electron carrier in cellular bioenergetics, cycling between its oxidised (NAD+) and reduced (NADH) forms across the citric acid cycle, glycolysis, beta-oxidation, and the electron transport chain. The molecule consists of two nucleotides, one bearing a nicotinamide base, the other bearing an adenine base, joined through their phosphate groups via a pyrophosphate linkage. The molecular mass is approximately 663.4 Da.
NAD+ is a coenzyme, not a peptide. It is included in the BodyPharm UAE research compound catalogue and follows similar research-use-only framing and pen-format supply, but it is structurally distinct from the peptide compounds (BPC-157, MOTS-c, retatrutide, and so on). The shared framing reflects shared research applications and supply infrastructure, not shared chemistry.
An NAD+ peptide pen is not a ballpoint pen, writing implement, or office supply, and despite the commercial naming convention NAD+ itself is not a peptide. The pen format refers to a pre-filled research delivery device loaded with reconstituted NAD+ at a fixed concentration.
NAD+ has no regulatory approval as a pharmaceutical in any jurisdiction. The compound is supplied as a research material for laboratory use only. The closely-related precursors NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) have been studied in human trials but have not received regulatory approval either.
How NAD+ differs from NMN and NR
NAD+ is the active coenzyme. NMN and NR are precursors that raise tissue NAD+ levels through the salvage pathway. NMN bypasses one enzymatic step (NAMPT) in the salvage pathway; NR is converted to NMN by nicotinamide riboside kinases (NRKs) and then to NAD+. The three compounds are studied in the same research literature because all increase the NAD+ pool, but they are distinct chemical entities.
Why NAD+ is written as NAD, NADH, or NAD plus
Four variant names and forms appear across the literature and commercial sources.
The oxidised form of nicotinamide adenine dinucleotide. The "+" indicates the positively-charged nicotinamide ring nitrogen. This is the form referenced in most cellular bioenergetics literature and the form supplied in research pen format.
NAD without the "+" is sometimes used generically to refer to the molecule across both oxidation states. NADH is the reduced form, generated when NAD+ accepts two electrons and a proton during redox reactions in the citric acid cycle, glycolysis, and beta-oxidation.
The full chemical name. The molecule consists of two nucleotides, one bearing a nicotinamide base, the other bearing an adenine base, joined through their phosphate groups via a pyrophosphate linkage. Discovered by Harden and Young in 1906; the modern understanding of its role in cellular bioenergetics emerged from the work of Warburg in the 1930s.
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors. They are distinct compounds from NAD+ itself but appear frequently in the same research literature because both raise tissue NAD+ levels through the salvage pathway. Research peptide pens supply NAD+, not the precursors.
mechanism of action.
NAD+ acts through four principal pathway threads in the research literature. The first is its classical role as a redox cofactor. The other three are consumption pathways where NAD+ is the substrate for enzymatic activity, not just a recyclable electron carrier.
NAD+ functions as the principal electron carrier in cellular bioenergetics, cycling between oxidised (NAD+) and reduced (NADH) forms across the citric acid cycle, glycolysis, beta-oxidation, and the electron transport chain. The redox cycling is the most fundamental role and the one shared with all eukaryotic cells.
Sirtuins (SIRT1-SIRT7) are NAD+-dependent deacetylases that regulate metabolism, DNA damage response, and gene expression. Imai and Guarente (Trends Cell Biol, 2014;24(8):464-471) reviewed how NAD+ availability is rate-limiting for sirtuin activity and how the age-related decline in tissue NAD+ contributes to age-associated metabolic dysfunction.
NAD+ is consumed (not just cycled) by poly-ADP-ribose polymerases (PARPs) during DNA damage repair and by CD38 in inflammatory signalling. The consumption pathways compete with sirtuins for NAD+ pool, providing the mechanistic basis for the "NAD+ depletion" framing common in aging biology research.
NAD+ is regenerated from nicotinamide via the salvage pathway, with nicotinamide phosphoribosyltransferase (NAMPT) as the rate-limiting enzyme. NMN and NR are intermediates that bypass NAMPT and raise tissue NAD+ levels (Mills et al, Cell Metab, 2016;24(6):795-806).
NAD+ and the aging biology framework
Imai and Guarente (Trends Cell Biol, 2014;24(8):464-471) reviewed the relationship between NAD+ availability, sirtuin activity, and age-related metabolic dysfunction. The published review framed declining tissue NAD+ as an Achilles' heel of cellular aging, with downstream effects on nuclear and mitochondrial function. The paper is a widely-cited entry point into the NAD+ aging-biology research field.
NMN precursor research in mouse models
Mills and colleagues (Cell Metab, 2016;24(6):795-806) reported a 12-month NMN administration study in wild-type C57BL/6N mice. The published findings reported that orally administered NMN was rapidly utilised to synthesise NAD+ in tissues, with downstream effects on body weight gain, energy metabolism, insulin sensitivity, plasma lipid profile, and age-associated gene expression changes. The work established the long-term NMN precursor research model.
NMN human trial in prediabetic postmenopausal women
Yoshino and colleagues (Science, 2021;372(6547):1224-1229) reported a 10-week randomised placebo-controlled trial of NMN supplementation (250 mg/day) in postmenopausal women with prediabetes. The published findings reported increased skeletal muscle insulin signalling and insulin sensitivity in the NMN arm, with elevated NAD+ levels in peripheral blood mononuclear cells. The work is the most commonly cited human NMN trial.
All effects described in this section have been observed in published research. Findings on NMN do not directly translate to claims about NAD+ supplementation; the two are distinct compounds in distinct pharmacokinetic contexts. The Mills and Yoshino work is referenced here for research context.
References
The three primary peer-reviewed sources referenced in this guide. Researchers should consult the originals for full methods, endpoints, and context.
- Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464-471. doi:10.1016/j.tcb.2014.04.002.
- Mills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 2016;24(6):795-806. doi:10.1016/j.cmet.2016.09.013.
- Yoshino M, Yoshino J, Kayser BD, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. doi:10.1126/science.abe9985.
research applications.
NAD+ appears across four principal research application areas in the published literature. The compound's role as a fundamental coenzyme means it touches a much broader literature than any peptide; the four areas below are the ones where NAD+ is studied as a direct or indirect intervention.
Cellular bioenergetics research
The classical research application area. Investigators studying mitochondrial function, the electron transport chain, and the relationship between NAD+/NADH ratio and metabolic state use NAD+ as a research tool. This area predates the sirtuin literature by decades and remains active.
Sirtuin pathway and aging biology research
The most heavily published modern application area. The Imai and Guarente 2014 review provides a widely-cited research entry point. Investigators use NAD+ and its precursors as research tools to probe sirtuin activity, the relationship between NAD+ availability and SIRT1-SIRT7 function, and age-related cellular dysfunction.
DNA damage and PARP substrate research
Poly-ADP-ribose polymerases (PARPs) consume NAD+ during DNA damage repair. Investigators studying genomic stability, oncology research, and the balance between sirtuin and PARP NAD+ consumption use NAD+ as a substrate research tool.
Precursor pathway research (NMN, NR)
The Mills 2016 mouse paper and the Yoshino 2021 human paper anchor the precursor research literature. Investigators studying NMN and NR pharmacokinetics, salvage-pathway dynamics, and tissue NAD+ replenishment use NAD+ as the downstream measurement target. BodyPharm UAE supplies NAD+ directly, not the precursors.
the research pen format.
A research pen is a pre-filled delivery device pre-loaded with reconstituted compound at a fixed concentration. The format originated in clinical injection devices and has been adapted for research handler use where dose consistency across experiments matters more than per-experiment flexibility.
For NAD+ specifically, the pen format addresses a particular practical challenge: reconstituted NAD+ in solution is comparatively unstable and oxidation-sensitive. The pre-filled sealed pen provides cleaner stability than repeated manual reconstitution of lyophilised vials would, particularly across the GCC summer months when ambient temperature management is challenging.
The trade-off is rigidity. A pen format locks in the concentration set at manufacture, so researchers who need to vary working dilutions across a study still need to dilute the drawn aliquot into their experimental buffer. For a single-concentration study or a series of replicates at the same dose, the format reduces handler variance considerably.
The BodyPharm UAE NAD+ research pen is supplied at a fixed concentration with batch-specific HPLC purity and mass spectrometry confirmation on the CoA.
quality and coa standards.
Research-grade NAD+ is defined by the documentation that accompanies it. A coenzyme with a published synthesis route but no batch-specific Certificate of Analysis is not a research material; it is an unknown. NAD+ is particularly demanding because of its oxidation sensitivity, so the CoA should document not just purity but stability handling.
- HPLC purity greater than 98 percent, ideally above 99 percent for sensitive research applications.
- Mass spectrometry confirmation of the NAD+ molecular mass (663.4 Da).
- Documented batch concentration and stability information.
- Batch-specific Certificate of Analysis from an independent third-party lab, not just an in-house result.
- Endotoxin testing where the material is intended for cell culture or animal research.
- Documented cold-chain handling from synthesis through shipping, with temperature logs available on request.
For BodyPharm UAE NAD+, the per-batch lab report is published at /uae/lab-results/nad-plus-pen. The CoA documents HPLC purity, mass spectrometry confirmation of the NAD+ molecular mass, and the in-house concentration assay. Independent third-party reports are available on request.
If there is no CoA, there is no compound. Only powder.
uae sourcing and regulatory context.
Research compounds are not pharmaceuticals under UAE Federal Decree-Law No. 38 of 2024 and are not regulated as medicines. NAD+ in the research compound format is supplied for laboratory research use only, not for human or veterinary therapeutic use. Researchers are responsible for ensuring their handling and use comply with their institution's research governance and any applicable local research-ethics requirements.
The UAE has emerged as a regional hub for research compound supply, partly because of the climate-driven cold-chain expertise developed across the GCC pharmaceutical distribution network. NAD+ is particularly sensitive to cold-chain integrity because of its oxidation sensitivity in solution. See peptide delivery and GCC cold chain for the operational considerations.
For the full UAE regulatory context covering research compound procurement, see Is it legal to buy peptides in Dubai and the UAE.
frequently asked questions.
The questions below cover the most common queries from UAE-based researchers and procurement teams. Each answer is independently sourced and can be cross-referenced against the linked product pages and lab results.
What does NAD+ stand for?
NAD+ stands for nicotinamide adenine dinucleotide, in its oxidised form. The "+" denotes the positively-charged nicotinamide ring nitrogen. NAD+ is a coenzyme present in all eukaryotic cells and functions as the principal electron carrier in cellular bioenergetics. It is technically a coenzyme, not a peptide, but is commonly supplied alongside research peptides in pen format.
Is NAD+ a peptide?
No. NAD+ is a dinucleotide coenzyme, not a peptide. It is included in the BodyPharm UAE research compound catalogue and follows similar research-use-only framing, but it is structurally distinct from the peptide compounds (BPC-157, MOTS-c, retatrutide, etc.). The shared framing reflects shared research applications and supply infrastructure, not shared chemistry.
What is the difference between NAD+, NMN, and NR?
NAD+ is the active coenzyme. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors that raise tissue NAD+ levels through the salvage pathway. NMN and NR are distinct compounds but are studied in the same research literature because all three increase the NAD+ pool. BodyPharm UAE supplies NAD+ directly in the research pen format, not NMN or NR.
Is NAD+ FDA approved?
No. NAD+ has no FDA approval as a pharmaceutical. It is supplied as a research compound for laboratory use only. NMN and NR (precursors) have been studied in human trials but have not received regulatory approval as therapeutic agents in any jurisdiction.
What is an NAD+ peptide pen?
An NAD+ research pen is a pre-filled delivery device loaded with reconstituted NAD+ solution at a fixed concentration. The pen format provides dosing consistency, sterility through the device seal, and removes the need for laboratory reconstitution at the point of use. Despite the "peptide pen" framing common in commercial listings, NAD+ is a coenzyme, not a peptide.
Where can I buy NAD+ in Dubai or the UAE?
BodyPharm UAE supplies NAD+ in the pre-filled research pen format with HPLC-verified purity and independent third-party Certificates of Analysis. Same-day delivery is available across Dubai, with one to three day delivery to other emirates. The product page at /uae/product/nad-plus-pen carries the current batch information.
What research applications use NAD+?
NAD+ research applications cover cellular bioenergetics, sirtuin pathway pharmacology, age-related metabolic decline, PARP and CD38 substrate research, and the precursor pathway literature (NMN, NR comparisons). The Imai and Guarente 2014 Trends in Cell Biology review and the Mills 2016 Cell Metabolism long-term NMN paper provide widely-cited research entry points.
How is NAD+ stored?
Lyophilised NAD+ is best stored at minus 20 degrees Celsius in opaque vials away from light and moisture. Reconstituted NAD+ in solution is relatively unstable and should be held at 2 to 8 degrees Celsius and used within the stability window documented on the Certificate of Analysis. The molecule is sensitive to oxidation, so reconstituted solution stability is shorter than most peptides.
related research peptides.
NAD+ sits within a broader research compound category that BodyPharm UAE supplies and documents in parallel. The references below provide background on adjacent research compounds frequently studied alongside NAD+.
A mitochondrial-derived peptide active in AMPK pathway research. The mitochondrial focus of both NAD+ and MOTS-c research makes them a natural pairing in cellular bioenergetics studies. Read more.
A copper-binding tripeptide with extensive matrix remodelling and gene expression literature. Researchers studying age-related cellular biology often examine GHK-Cu alongside NAD+ given overlap in gene expression pathways. Read more.
A GLP-1 / GIP / glucagon triple agonist studied across metabolic indications. Researchers comparing coenzyme-mediated metabolic effects with incretin-pathway approaches reference both NAD+ and retatrutide in metabolism reviews. Read more.
For the full BodyPharm UAE research peptide catalogue with current batch CoAs, see /uae/peptides.
HPLC-verified NAD+ in the pre-filled research pen format. Batch-specific CoA, same-day Dubai delivery.